<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The molecular mechanisms of the contribution of <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> type-1 receptor blockers to neuronal protection are still unclear </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we investigated the effect of <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> type-2 (AT2) receptor stimulation on neurons and cognitive function involving a new neuroprotective factor, <z:chebi fb="0" ids="25255">methyl methanesulfonate</z:chebi> sensitive 2 (MMS2) </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="2719,48432">Angiotensin II</z:chebi> treatment of neurospheres enhanced their differentiation and increased MMS2 expression </plain></SENT>
<SENT sid="3" pm="."><plain>Knockdown of the MMS2 gene by small interference <z:chebi fb="40" ids="33697">RNA</z:chebi> (siRNA) significantly reduced the number of neurospheres, with loss of sphere formation </plain></SENT>
<SENT sid="4" pm="."><plain>An <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> type-1 receptor blocker, <z:chebi fb="0" ids="9927">valsartan</z:chebi>, enhanced such neurosphere differentiation and MMS2 induction, whereas an AT2 receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, PD123319, inhibited them </plain></SENT>
<SENT sid="5" pm="."><plain>After mice underwent permanent middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp>, AT2 receptor <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression was significantly increased in the ischemic side of the brain </plain></SENT>
<SENT sid="6" pm="."><plain>Passive avoidance rate to evaluate cognitive function was significantly impaired in AT2 receptor null (Agtr2-) mice compared with <z:mp ids='MP_0002169'>wild-type</z:mp> mice </plain></SENT>
<SENT sid="7" pm="."><plain>Treatment with <z:chebi fb="0" ids="9927">valsartan</z:chebi> prevented the <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> in <z:mp ids='MP_0002169'>wild-type</z:mp> mice, but this effect was weaker in Agtr2- mice </plain></SENT>
<SENT sid="8" pm="."><plain>In ischemic brain regions, MMS2 was increased in <z:mp ids='MP_0002169'>wild-type</z:mp> mice, but not in Agtr2- mice </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="9927">Valsartan</z:chebi> also enhanced MMS2 expression to a greater degree in <z:mp ids='MP_0002169'>wild-type</z:mp> mice </plain></SENT>
<SENT sid="10" pm="."><plain>Finally, intracerebroventricular administration of MMS2 siRNA showed more impaired avoidance rate after middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> compared with that in control siRNA-transfected mice </plain></SENT>
<SENT sid="11" pm="."><plain>These findings experimentally support the clinical evidence and indicate a unique mechanism of the AT2 receptor in brain protection </plain></SENT>
</text></document>